Lupin enters into strategic distribution agreement with LG Life Sciences

06 Aug 2014 Evaluate

Lupin has entered into a strategic distribution agreement with LG Life Sciences (South Korea) to launch Insulin Glargine, a novel insulin analogue under the brand name Basugine. According to the agreement, Lupin would be responsible for marketing and sales of Basugine in India.

The overall diabetes market size within the Indian Pharmaceutical Market (IPM) stood at Rs 6,032 crore growing at 18%, as per IMS MAT April 2014. The total insulin analogue market size is valued at Rs 585 crore with 3 year CAGR of 24%. The total Glargine molecule market is Rs 218.5 crore with 3 year CAGR of 23%.

Lupin ranks second in the conventional insulin market and grew more than the market at 10.82% in April 2014, as per IMSD MAT, while the market grew at 8%. Lupin is amongst the fastest growing players in the OAD (Oral Anti-Diabetes Drugs) market and also in the insulin segment.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

Lupin Share Price

2120.00 -1.65 (-0.08%)
29-Jan-2026 13:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1597.90
Dr. Reddys Lab 1200.00
Cipla 1319.40
Zydus Lifesciences 887.50
Lupin 2120.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×